Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Annual Results: Standalone & Consolidated Reports

Annual Results

Results Snapshot

Figures in Million

Consolidate Annual Results

Dec'25

Dec'24

Dec'23

Dec'22

Dec'21

Dec'20

Dec'19

Net Sales

5,916.54

5,721.40

6,016.27

8,321.67

7,668.88

5,975.91

5,235.49

Other Operating Income

0.00

Total Operating income

5,916.54

5,721.40

6,016.27

8,321.67

7,668.88

5,975.91

5,235.49

Raw Material Cost

4,161.00

3,926.23

4,139.61

5,718.93

5,342.29

3,759.35

3,392.79

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

493.37

0.00

359.16

326.86

0.00

Power Cost

0.00

Manufacturing Expenses

83.21

166.42

263.76

299.12

262.38

307.42

315.61

Selling and Distribution Expenses

908.56

781.35

1,002.05

1,106.72

1,033.13

833.24

769.14

Other Expenses

-33.98

5.44

-7.24

-1.50

-36.12

-46.12

-15.40

Total Expenditure (Excl Depreciation)

5,306.38

4,928.43

5,332.98

7,109.73

6,635.75

4,765.71

4,323.50

Operating Profit (PBDIT) excl Other Income

610.2

793

683.3

1211.9

1033.1

1210.2

912

Other Income

168.70

383.33

98.30

350.39

-101.14

-149.50

804.21

Operating Profit (PBDIT)

1,129.39

1,518.99

236.11

1,867.41

968.74

1,329.82

1,941.73

Interest

83.21

166.42

263.76

299.12

262.38

307.42

315.61

Exceptional Items

-195.76

-41.39

-78.12

-118.75

76.99

555.61

138.38

Gross Profit (PBDT)

1,755.53

1,795.17

1,876.66

2,602.74

2,326.60

2,216.56

1,842.70

Depreciation

415.86

370.02

425.06

370.03

370.46

345.50

294.08

Profit Before Tax

434.57

941.16

-530.82

1,079.52

412.89

1,232.50

1,470.42

Tax

64.64

109.84

-139.42

133.92

-13.40

344.08

307.72

Provisions and contingencies

0.00

Profit After Tax

379.03

701.21

-865.50

845.50

290.20

1,150.90

1,201.22

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

379.03

701.21

-865.50

845.50

290.20

1,150.90

1,201.22

Share in Profit of Associates

0.00

Minority Interest

-7.43

-23.66

-20.89

-14.41

-8.92

-2.90

-17.92

Other related items

0.00

Consolidated Net Profit

371.60

677.55

-886.38

831.09

281.28

1,148.00

1,183.30

Equity Capital

0.00

Face Value

1.11

1.06

1.1

1.12

1.22

1.19

0.0

Reserves

13,400.23

12,928.76

13,116.44

13,821.96

13,959.12

13,717.14

8,218.33

Earnings per share (EPS)

0.26

0.48

-0.59

0.58

0.2

0.85

0.0

Diluted Earnings per share

0.26

0.48

-0.59

0.58

0.2

0.85

0.0

Operating Profit Margin (Excl OI)

9.21%

13.38%

-4.77%

13.78%

9.12%

18.97%

16.11%

Gross Profit Margin

14.37%

22.92%

-1.76%

17.42%

10.21%

26.41%

33.7%

PAT Margin

6.41%

12.26%

-14.39%

10.16%

3.78%

19.26%

22.94%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Annual Analysis Highlights

Net Sales

YoY Growth in year ended Dec 2025 is 3.41% vs -4.90% in Dec 2024

Consolidate Net Profit

YoY Growth in year ended Dec 2025 is -45.16% vs 176.44% in Dec 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2025 is -15.41% vs 724.17% in Dec 2024

Interest

YoY Growth in year ended Dec 2025 is -50.00% vs -36.92% in Dec 2024

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2025 has fallen from Dec 2024

Compare Annual Results Of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. With

Select Peers

Figures in Million

Consolidate Annual Results

Change(HKD)

Change(%)

Net Sales

5,916.54

41.65

5,874.89

14,105.38%

Other Operating Income

0.00

Total Operating income

5,916.54

41.65

5,874.89

14,105.38%

Raw Material Cost

4,161.00

60.61

4,100.39

6,765.20%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

493.37

160.24

333.13

207.89%

Power Cost

0.00

Manufacturing Expenses

83.21

6.24

76.97

1,233.49%

Selling and Distribution Expenses

908.56

94.11

814.45

865.42%

Other Expenses

-33.98

-0.13

-33.85

-26,038.46%

Total Expenditure (Excl Depreciation)

5,306.38

319.96

4,986.42

1,558.45%

Operating Profit (PBDIT) excl Other Income

610.16

-278.31

888.47

319.24%

Other Income

168.70

35.19

133.51

379.40%

Operating Profit (PBDIT)

1,129.39

-952.42

2,081.81

218.58%

Interest

83.21

6.24

76.97

1,233.49%

Exceptional Items

-195.76

22.86

-218.62

-956.34%

Gross Profit (PBDT)

1,755.53

-18.96

1,774.49

9,359.12%

Depreciation

415.86

43.72

372.14

851.19%

Profit Before Tax

434.57

-979.52

1,414.09

144.37%

Tax

64.64

0.00

64.64

Provisions and contingencies

0.00

Profit After Tax

379.03

-979.52

1,358.55

138.70%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

379.03

-979.52

1,358.55

138.70%

Share in Profit of Associates

0.00

Minority Interest

-7.43

0.00

-7.43

Other related items

0.00

Consolidated Net Profit

371.60

-979.52

1,351.12

137.94%

Equity Capital

0.00

Face Value

1.11

0.00

Reserves

13,400.23

-1,741.37

15,141.60

869.52%

Earnings per share (EPS)

0.26

-0.78

1.04

133.33%

Diluted Earnings per share

0.26

-0.78

1.04

133.33%

Operating Profit Margin (Excl OI)

9.21%

-2,475.88%

0.00

2,485.09%

Gross Profit Margin

14.37%

-2,246.56%

0.00

2,260.93%

PAT Margin

6.41%

-2,351.51%

0.00

2,357.92%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Annual - Net Sales

Net Sales 591.65 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is 3.41% vs -4.90% in Dec 2024

Annual - Consolidate Net Profit

Consolidate Net Profit 37.16 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is -45.16% vs 176.44% in Dec 2024

Annual - Operating Profit (PBDIT)

Operating Profit (PBDIT) 96.07 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is -15.41% vs 724.17% in Dec 2024

Annual - Interest

Interest 8.32 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is -50.00% vs -36.92% in Dec 2024

Annual - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 9.21%

in Dec 2025

Figures in %

YoY Growth in year ended Dec 2025 has fallen from Dec 2024